Mirae Asset Global Investments Co. Ltd. Lowers Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Mirae Asset Global Investments Co. Ltd. lowered its position in BioNTech SE (NASDAQ:BNTX) by 54.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 36,813 shares of the company’s stock after selling 44,290 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in BioNTech were worth $3,885,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Eagle Bay Advisors LLC purchased a new position in shares of BioNTech in the second quarter valued at about $33,000. State of Wyoming bought a new stake in BioNTech during the 2nd quarter valued at approximately $26,000. Covestor Ltd purchased a new position in BioNTech in the 3rd quarter worth approximately $32,000. Resurgent Financial Advisors LLC purchased a new position in BioNTech in the 4th quarter worth approximately $47,000. Finally, UMB Bank n.a. bought a new position in BioNTech in the 4th quarter worth approximately $50,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BNTX shares. UBS Group reduced their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. The Goldman Sachs Group decreased their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 28th. JPMorgan Chase & Co. cut their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. Finally, HC Wainwright decreased their target price on BioNTech from $133.00 to $107.00 and set a “buy” rating on the stock in a research report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Stock Down 1.8 %

Shares of NASDAQ:BNTX opened at $86.34 on Wednesday. The company has a market cap of $20.53 billion, a price-to-earnings ratio of 20.96 and a beta of 0.23. BioNTech SE has a 12 month low of $85.21 and a 12 month high of $129.10. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $91.67 and a 200 day moving average price of $97.64.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. As a group, equities research analysts predict that BioNTech SE will post -1.67 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.